EHA 2022 | Upcoming trials and agents in T-cell lymphoma
In this video, Kate Cwynarski, FRCP, FRCPath, PhD, University College Hospitals London NHS Foundation Trust, London, UK, and Gloria Iacoboni, MD, Hospital Universitari Vall d’Hebron, Barcelona, Spain, hold a fascinating discussion on current and future treatment approaches in T-cell lymphoma. Dr Cwynarski and Dr Iacoboni first highlight some novel agents in the field, and then go on to discuss different targets being investigated, such as CD7, CD70 and CD30. Following this, Dr Cwynarski and Dr Iacoboni share some insights into the AUTO4-TL1 trial evaluating the safety and efficacy of AUTO4, a TRBC1-targeting CAR-T cell therapy in T-cell lymphoma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Kate Cwynarski: Roche and Kite: Advisory Board, Speakers Bureau, Conference Support
Janssen: Advisory Board
